<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053715</url>
  </required_header>
  <id_info>
    <org_study_id>CE1250_5002_EU</org_study_id>
    <secondary_id>1501</secondary_id>
    <nct_id>NCT01053715</nct_id>
  </id_info>
  <brief_title>Quality of Life Study of Helixate NexGen</brief_title>
  <official_title>A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients With Moderate or Severe Haemophilia A Using Helixate NexGen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents
      and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The
      study will also assess the kinds of determinants, including key transitional life events,
      that might impact HRQoL in this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health Related Quality of Life (HRQoL)</measure>
    <time_frame>baseline and every 12 months over 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HRQoL due to pre-specified factors potentially affecting HRQoL in patients with hemophilia</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HRQoL due to transitional life events</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">78</enrollment>
  <condition>Hemophilia A</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of moderate or severe Hemophilia A using Helixate NexGen
        identified by selected European hemophilia treatment centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Haemophilia A patient

          -  Severely (&lt;1%) and moderately (1-5%) affected

          -  On treatment with Helixate NexGen

          -  Ability to read and understand study materials (patient information and data
             protection form, patient-related questionnaires)

          -  Signed data protection form; if patient is &lt;18 years of age, legal guardian must also
             give written consent by signing the data protection form

        Exclusion Criteria:

          -  Presence of inhibitors

          -  Abuse of recreational drugs or alcohol interfering with the every-day-life in the
             opinion of the physician

          -  Advanced stage human immunodeficiency virus (HIV) infection (CD4 cell counts &lt;200/cmm,
             multi-drug resistance, presence of AIDS related signs or symptoms)

          -  Symptomatic liver disease (cirrhosis, ascites, esophageal varices)

          -  Concomitant or planned interferon therapy

          -  Malignancies on or off treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Klamroth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hämophiliezentrum, Vivantes-Klinikum im Friedrichshain Zentrum für Gefäßmedizin, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Gringeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.R.C.C.S. Fondazione Ospedale Maggiore Policlinico, Milan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CSLB Study Site 22</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 26</name>
      <address>
        <city>Grieskirchen</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 24</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 29</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 23</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 25</name>
      <address>
        <city>St. Pölten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 20</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 21</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 27</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 52</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 51</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 65</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 68</name>
      <address>
        <city>Poitiers Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 60</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 64</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 66</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 1</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 3</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 2</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 6</name>
      <address>
        <city>Delmenhorst</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 7</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 4</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 72</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 71</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 74</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 73</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 98</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 95</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 91</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 35</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSLB Study Site 36</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT01053715&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

